Technical Analysis for CNST - Constellation Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade C 6.07 3.41% 0.20
CNST closed up 3.41 percent on Thursday, December 13, 2018, on 32 percent of normal volume. It ran into resistance at its 50 day moving average. The price action carved out a bearish shooting star candlestick pattern. That may indicate a downside reversal. Look for price to trade beneath the low of the shooting star for confirmation.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical CNST trend table...

Date Alert Name Type % Chg
Dec 13 50 DMA Resistance Bearish 0.00%
Dec 13 Shooting Star Candlestick Bearish 0.00%
Dec 13 Lizard Bearish Bearish Day Trade Setup 0.00%
Dec 13 Upper Bollinger Band Touch Strength 0.00%
Dec 12 Slingshot Bearish Bearish Swing Setup 3.41%
Dec 12 Crossed Above 20 DMA Bullish 3.41%
Dec 12 Upper Bollinger Band Touch Strength 3.41%
Dec 11 20 DMA Resistance Bearish 5.93%
Dec 11 Volume Surge Other 5.93%
Dec 11 Down 3 Days in a Row Weakness 5.93%

Older signals for CNST ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Constellation Pharmaceuticals, Inc. is a United States-based company, which discovers and develops small molecule therapeutics for the treatment of cancer, inflammatory/immunologic disorders and other diseases. The Company has two clinical-stage oncology development programs: the first program is evaluating a compound, CPI-0610, and the other program is evaluating a compound, CPI-1205. CPI-0610 is a small molecule that inhibits the binding of bromodomain and extra terminal (BET) proteins to chromatin. CPI-1205 is a small molecule that inhibits an enzyme, Enhancer of Zeste Homolog 2 (EZH2). It is in a Phase I clinical study of CPI-0610 in patients with progressive lymphoma; a Phase I clinical study of CPI-0610 in patients with acute leukemia, myelodysplastic syndrome or myelodysplastic/myeloproliferative neoplasms; a Phase I clinical study of CPI-0610 in patients with previously treated multiple myeloma, and a Phase 1 clinical study of CPI-1205 in patients with lymphoma.
Is CNST a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 11.97
52 Week Low 5.57
Average Volume 23,077
200-Day Moving Average 0.0
50-Day Moving Average 6.2019
20-Day Moving Average 5.8473
10-Day Moving Average 5.917
Average True Range 0.4172
ADX 24.45
+DI 26.4588
-DI 12.1447
Chandelier Exit (Long, 3 ATRs ) 5.2484
Chandelier Exit (Short, 3 ATRs ) 6.8216
Upper Bollinger Band 6.0819
Lower Bollinger Band 5.6127
Percent B (%b) 0.97
BandWidth 8.024216
MACD Line -0.0825
MACD Signal Line -0.1344
MACD Histogram 0.0519
Fundamentals Value
Market Cap 10.77 Million
Num Shares 1.77 Million
EPS -49.87
Price-to-Earnings (P/E) Ratio -0.12
Price-to-Sales 0.00
Price-to-Book 0.23
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.93
Resistance 3 (R3) 6.97 6.74 6.78
Resistance 2 (R2) 6.74 6.52 6.71 6.73
Resistance 1 (R1) 6.40 6.38 6.57 6.36 6.69
Pivot Point 6.17 6.17 6.25 6.14 6.17
Support 1 (S1) 5.83 5.95 6.00 5.79 5.45
Support 2 (S2) 5.60 5.81 5.57 5.41
Support 3 (S3) 5.26 5.60 5.36
Support 4 (S4) 5.22